Notes
2019 US dollars
References
1. Jiang Y, et al. A Budget Impact Analysis of Fidaxomicin for the Management of Clostridioides Difficile Infection in the United States. 25th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. N/A, 18 May 2020. Available from: URL: https://www.ispor.org/heor-resources/presentations-database/presentation/intl2020-3182/99290
2. hen J, et al. Cost-Effectiveness of Bezlotoxumab and Fidaxomicin for Recurrent C. Difficile Infection. 25th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : abstr. N/A, 18 May 2020. Available from: URL: https://www.ispor.org/heor-resources/presentations-database/presentation/intl2020-3182/102341
Rights and permissions
About this article
Cite this article
Economic evaluations of fidaxomicin for Clostridium difficile infection. PharmacoEcon Outcomes News 855, 11 (2020). https://doi.org/10.1007/s40274-020-6876-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-6876-4